Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17466271rdf:typepubmed:Citationlld:pubmed
pubmed-article:17466271lifeskim:mentionsumls-concept:C0664336lld:lifeskim
pubmed-article:17466271lifeskim:mentionsumls-concept:C0162638lld:lifeskim
pubmed-article:17466271lifeskim:mentionsumls-concept:C0018873lld:lifeskim
pubmed-article:17466271lifeskim:mentionsumls-concept:C0538927lld:lifeskim
pubmed-article:17466271lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:17466271lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:17466271lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:17466271lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:17466271lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:17466271pubmed:issue4lld:pubmed
pubmed-article:17466271pubmed:dateCreated2007-5-14lld:pubmed
pubmed-article:17466271pubmed:abstractTextThe effect of celecoxib, a cyclooxygenase-2 selective inhibitor, on a human cervical cancer cell line, HeLa cells, was examined. We found that celecoxib increased DNA ladder formation and the activity of caspase-3, indicating that celecoxib induced apoptosis in HeLa cells. Celecoxib suppressed the expression of an anti-apoptotic protein, survivin, in both protein and mRNA levels. The overexpression of survivin overrode caspase-3 activation induced by celecoxib. Subsequently, we performed luciferase reporter assay with the reporter vector containing human survivin promoter region and electrophoretic mobility shift assay and found that the -75 to -66 bp region relative to the initiating codon played an important role in celecoxib action to suppress survivin promoter activity. Our findings might provide a new insight into the anti-cancer effects of celecoxib.lld:pubmed
pubmed-article:17466271pubmed:languageenglld:pubmed
pubmed-article:17466271pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17466271pubmed:citationSubsetIMlld:pubmed
pubmed-article:17466271pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17466271pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17466271pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17466271pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17466271pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17466271pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17466271pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17466271pubmed:statusMEDLINElld:pubmed
pubmed-article:17466271pubmed:monthJunlld:pubmed
pubmed-article:17466271pubmed:issn0006-291Xlld:pubmed
pubmed-article:17466271pubmed:authorpubmed-author:MorimotoSachi...lld:pubmed
pubmed-article:17466271pubmed:authorpubmed-author:ShiraishiFumi...lld:pubmed
pubmed-article:17466271pubmed:authorpubmed-author:SasaguriToshi...lld:pubmed
pubmed-article:17466271pubmed:authorpubmed-author:MiwaYoshikazu...lld:pubmed
pubmed-article:17466271pubmed:authorpubmed-author:Takahashi-Yan...lld:pubmed
pubmed-article:17466271pubmed:authorpubmed-author:FukadaKazuhir...lld:pubmed
pubmed-article:17466271pubmed:authorpubmed-author:Sakoguchi-Oka...lld:pubmed
pubmed-article:17466271pubmed:issnTypePrintlld:pubmed
pubmed-article:17466271pubmed:day15lld:pubmed
pubmed-article:17466271pubmed:volume357lld:pubmed
pubmed-article:17466271pubmed:ownerNLMlld:pubmed
pubmed-article:17466271pubmed:authorsCompleteYlld:pubmed
pubmed-article:17466271pubmed:pagination1166-71lld:pubmed
pubmed-article:17466271pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:17466271pubmed:meshHeadingpubmed-meshheading:17466271...lld:pubmed
pubmed-article:17466271pubmed:meshHeadingpubmed-meshheading:17466271...lld:pubmed
pubmed-article:17466271pubmed:meshHeadingpubmed-meshheading:17466271...lld:pubmed
pubmed-article:17466271pubmed:meshHeadingpubmed-meshheading:17466271...lld:pubmed
pubmed-article:17466271pubmed:meshHeadingpubmed-meshheading:17466271...lld:pubmed
pubmed-article:17466271pubmed:meshHeadingpubmed-meshheading:17466271...lld:pubmed
pubmed-article:17466271pubmed:meshHeadingpubmed-meshheading:17466271...lld:pubmed
pubmed-article:17466271pubmed:meshHeadingpubmed-meshheading:17466271...lld:pubmed
pubmed-article:17466271pubmed:meshHeadingpubmed-meshheading:17466271...lld:pubmed
pubmed-article:17466271pubmed:meshHeadingpubmed-meshheading:17466271...lld:pubmed
pubmed-article:17466271pubmed:meshHeadingpubmed-meshheading:17466271...lld:pubmed
pubmed-article:17466271pubmed:year2007lld:pubmed
pubmed-article:17466271pubmed:articleTitleCelecoxib induces apoptosis by inhibiting the expression of survivin in HeLa cells.lld:pubmed
pubmed-article:17466271pubmed:affiliationDepartment of Clinical Pharmacology, Faculty of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.lld:pubmed
pubmed-article:17466271pubmed:publicationTypeJournal Articlelld:pubmed